Detection of numerical chromosome 17 abnormalities in fine-needle aspirates of breast cancer using a novel in situ hybridization signal amplification method

Schmitt, Fernando; Soares, Raquel; Leitão, Dina

doi:10.1002/(sici)1097-0339(199808)19:2<141::aid-dc16>3.0.co;2-f

Cited by 4 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29–50 Setting of these thresholds is complicated not only by genomic heterogeneity and proliferative activity of tumours, but also by the substantial nuclear truncation resulting from tissue sectioning. Control specimens used to set these thresholds have included human lymphocytes,29,31,33,50 cholangiocarcinoma cell-line controls,31,51,52 benign breast-lesions or biopsies (eg, fibroadenomas, sclerosing adenosis),38,53 healthy breast tissue,30,32,36,40,54,55 and paired healthy breast tissue 36. Typically, 5–30% of cells displayed monosomy and less than 5% displayed polysomy in healthy (control) epithelium 10,56–58…”

Section: Identification Of Aneusomy 17mentioning

confidence: 99%

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

Reinholz

Bruzek

Visscher

et al. 2009

The Lancet Oncology

View full text Add to dashboard Cite

Abnormalities of chromosome 17, recognised over two decades ago to be important in tumorigenesis, often occur in breast cancer. Changes of specific loci on chromosome 17 including ERBB2 amplification, P53 loss, BRCA1 loss, and TOP2A amplification or deletion are known to have important roles in breast-cancer pathophysiology. Numerical aberrations of chromosome 17 are linked to breast-cancer initiation and progression, and possibly to treatment response. However, the clinical importance of chromosome 17 anomalies, in particular the effect on ERBB2 protein expression, is unknown. Reports are conflicting regarding the association of copy gain of chromosome 17 (polysomy 17) with strong ERBB2 protein expression in the absence of true ERBB2 gene amplification. Copy-number anomalies in chromosome 17 seem to be common in tumours that show discrepant ERBB2 expression and in tumours with discordant ERBB2-protein and ERBB2 gene copy number measurements. The mechanisms of ERBB2 dosage changes—gene amplification versus chromosome gain and loss—probably differ in primary and metastatic disease; however, a correction for chromosome 17 copy-number is necessary to completely distinguish between these mechanisms. A better understanding of how polysomy 17 affects gene-copy number and protein expression will help to select patients who will respond to therapies targeting ERBB2 and other protein products of chromosome 17 loci.

show abstract

Section: Identification Of Aneusomy 17mentioning

confidence: 99%

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

Reinholz

Bruzek

Visscher

et al. 2009

The Lancet Oncology

View full text Add to dashboard Cite

show abstract

Fluorescence in situ hybridization, comparative genomic hybridization, and other molecular biology techniques in the analysis of effusions

Reis‐Filho

Schmitt

2005

Diagnostic Cytopathology

View full text Add to dashboard Cite

Over the last 20 yr, the introduction of immunocytochemistry as a diagnostic tool has dramatically revolutionized diagnostic pathology. With the introduction of molecular methods as part of the diagnostic armamentarium, the practicing pathologist is facing the new challenge of grasping novel concepts of the molecular cytogenetics era. Herein, we review the diagnostic contribution of ancillary molecular techniques, including fluorescent and chromogenic in situ hybridization, telomerase assays, loss of heterozygosity, comparative genomic hybridization (CGH), and microarray-based CGH, for the practicing cytopathologists and discuss how these techniques will help pathologists in decision-making.

show abstract

MicroRNA-21 Expression in Primary Breast Cancer Tissue Among Egyptian Female Patients and its Correlation with Chromosome 17 Aneusomy

et al. 2015

View full text Add to dashboard Cite

show abstract

Detection of numerical chromosome 17 abnormalities in fine-needle aspirates of breast cancer using a novel in situ hybridization signal amplification method

Cited by 4 publications

References 15 publications

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

Fluorescence in situ hybridization, comparative genomic hybridization, and other molecular biology techniques in the analysis of effusions

MicroRNA-21 Expression in Primary Breast Cancer Tissue Among Egyptian Female Patients and its Correlation with Chromosome 17 Aneusomy

Contact Info

Product

Resources

About